Celldex Company's products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines.

Most Read News